RecruitingPhase 4NCT07191873
Rare condition
Idiopathic intracranial hypertension
11
studies recruiting now
as of 7 Sept 2026
56
studies registered in total
as of 7 Sept 2026
5
countries with a recruiting site
as of 7 Sept 2026
27 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06913712
BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment
RecruitingNot applicableNCT06945848
Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide
RecruitingNot applicableNCT07440277
IIH Intervention: A Clinical Trial Comparing 2 Treatments (Shunts and Stents) Evaluation Of Clinical Effectiveness And Cost Effectiveness
RecruitingPhase 3NCT05707442
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 11 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Idiopathic intracranial hypertension study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Idiopathic intracranial hypertension
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Semaglutide (Ozempic)
Phase 3Acetazolamide (Acetazolamide)
Phase 2Azd-4017
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).